Concepedia

Paul V. Kaplita

PV

22

Publications

975

Citations

16

H-Index

1982

Active since

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (Germany)

Sterling Research Group (United States)

Sterling Research Group

Boehringer Ingelheim (France)

Paul V. Kaplita is an author at Boehringer Ingelheim (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

MedicinePharmacologyDrug DiscoveryBiochemistryPharmacotherapyNatural SciencesMedicinal ChemistryPhysiologyDrug DevelopmentMolecular Pharmacology

Publications per year

1982–2012

22

Publications

22

Identification of pharmacological inhibitors of the MEK5/ERK5 pathway

Revati J. Tatake, Margaret M. O’Neill, Charles A. Kennedy et al. · Biochemical and Biophysical Research Communications · 2008 · 154 citations

Medicine, Receptor Tyrosine Kinase, Mechanism Of Action +4

γ-Aminobutyric acid action in guinea-pig ileal myenteric plexus

Paul V. Kaplita, Donald H. Waters, David J. Triggle · European Journal of Pharmacology · 1982 · 113 citations

Animal Physiology, γ-Aminobutyric Acid Action, Gastrointestinal Pharmacology +7

Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence

Alfred J. Kolb, Paul V. Kaplita, Dave J. Hayes et al. · Drug Discovery Today · 1998 · 78 citations

Single Molecule Biophysics, Signal Transduction, Natural Sciences +8

Discovery of potent and selective PKC-θ inhibitors

Charles L. Cywin, Georg Dahmann, Anthony S. Prokopowicz et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 69 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Drug Target +7

Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies

Tina M. Morwick, Angela Berry, Janice R. Brickwood et al. · Journal of Medicinal Chemistry · 2006 · 67 citations · Full text

Rows per page

1–5 of 22